
|Videos|August 12, 2021
Dr. Susan Slovin summarizes state of PARP inhibitor use in prostate cancer
Author(s)Urology Times staff
Advertisement
Susan F. Slovin, MD, PhD, medical oncologist, associate vice chair, Academic Administration, Department of Medicine, Memorial Sloan Kettering Cancer Center, provides a concise summary of the latest information on the state of PARP inhibitors for the treatment of patients with prostate cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












